Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
NASDAQ:PYPD
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.6Last Year’s EPS
-1.25Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 25.83%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress and positive indicators for D-PLEX100, with successful trial enrollment and strong market potential. However, financial challenges such as increased net loss and R&D expenses present notable concerns.Company Guidance
During PolyPid's First Quarter 2025 earnings call, detailed guidance was provided regarding the anticipated progress of the company's flagship product, D-PLEX100. The management highlighted the successful enrollment of 800 patients in the SHIELD 2 Phase 3 trial, with top-line data expected by the end of June 2025. The company is preparing for potential New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions in early 2026. Financially, PolyPid reported cash and cash equivalents of $8 million as of March 31, 2025, projecting a cash runway into the third quarter of 2025, supported by a $15 million financing round completed in December 2024. There is potential for an additional $27 million from warrant exercises. Research and development expenses increased to $6.1 million due to the ramp-up of the SHIELD 2 trial, contributing to a net loss of $8.3 million for the quarter. The company is also actively engaged in U.S. and European partnership discussions to support the commercialization of D-PLEX100, with a focus on securing a partner with a dedicated hospital product sales force.Successful Conclusion of SHIELD 2 Enrollment
PolyPid successfully concluded enrollment of the SHIELD 2 Phase 3 trial assessing the efficacy of D-PLEX100 for preventing surgical site infections in abdominal colorectal surgery.
Positive Indicators for D-PLEX100
The independent Data Safety Monitoring Board recommended concluding the SHIELD 2 trial at 800 patients, suggesting positive efficacy signals from D-PLEX100.
Strong U.S. Market Potential for D-PLEX100
The total addressable market for D-PLEX100 in the U.S. is estimated at over 12 million surgeries annually, with 4.4 million being abdominal soft tissue surgeries.
Advanced Partnering Discussions
PolyPid is in advanced discussions with multiple potential partners for U.S. commercialization of D-PLEX100, with significant partnering interest.
Solid Financial Position
PolyPid has $8 million in cash and cash equivalents, sufficient to fund operations into the third quarter of 2025.
PYPD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PYPD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $2.71 | $2.90 | +7.01% |
Feb 12, 2025 | $2.88 | $2.97 | +3.13% |
Nov 13, 2024 | $3.50 | $3.40 | -2.86% |
Aug 14, 2024 | $3.56 | $3.49 | -1.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PolyPid Ltd. (PYPD) report earnings?
PolyPid Ltd. (PYPD) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is PolyPid Ltd. (PYPD) earnings time?
PolyPid Ltd. (PYPD) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PYPD EPS forecast?
PYPD EPS forecast for the fiscal quarter 2025 (Q2) is -0.6.